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Background: This study aims to evaluate the role of NT-proBNP and six minute walking
distance (6MWD) in the pre- and post-operative assessment of subjects undergoing pulmonary
endarterectomy (PEA) for chronic thromboembolic pulmonary hypertension (CTEPH).
Methods: Subjects undergoing PEA between August 2004 and July 2006 were assessed at
baseline and 3 months post-operatively with resting haemodynamics, NT-proBNP and
6MWD.
Results: A number of 111 subjects underwent surgery, of which 102 were included. 15
subjects died before their 3 month assessment. Non-survivors had significantly worse
preoperative NT-proBNP and 6MWD (4728 pg/mL vs 1863 pg/mL, p ¼ 0.001, 182.4m vs
263.5m, p ¼ 0.001). Taking pre-operative cut-off values of 1200 pg/mL for NT-proBNP and
345m for 6MWD, both tests had high negative predictive value for predicting mortality
(97.3% and 100%, respectively). Amongst survivors, peri-operative changes in NT-proBNP
and 6MWD correlated with changes in total pulmonary resistance (TPR) (r ¼ 0.49, po0.001
and r ¼ 0.46, po0.001). Post-operatively, both NT-proBNP and 6MWD also correlated
with mPAP (r ¼ 0.65, po0.001 and r ¼ 0.50, po0.001) and PVR (r ¼ 0.63, po0.001 and
r ¼ 0.47, po0.001). The ability of NT-proBNP to predict persistent pulmonary
hypertension was significantly confounded by age, but not gender, BMI or renal function.
Conclusions: Pre-operative evaluation with NT-proBNP and 6MWD helps risk-stratify
patients prior to PEA. Post-operatively, both markers correlate with changes in disease
burden and right ventricular function. These results suggest that both NT-proBNP and
6MWD offer effective ‘bedside’ tools for the long term follow up of patients with CTEPH.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
0 830541x4627; fax: +44 1480 364998.
papworth.nhs.uk (J. Pepke-Zaba).
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NT-proBNP and 6MWD in CTEPH 2255Introduction MethodsChronic thromboembolic pulmonary hypertension (CTEPH) is
generally considered to represent a rare consequence of
acute pulmonary embolic disease.1 Following an acute
event, thrombus fails to adequately resolve and organises,
resulting in chronic obstruction of the pulmonary vascula-
ture. Untreated, this causes progressively worsening pul-
monary hypertension, right ventricular dysfunction and
death.2 Early recognition is crucial, as selected patients
with favourable disease distribution can benefit from
surgical intervention (pulmonary endarterectomy or PEA).
This complex procedure, in which thrombotic material is
removed under circulatory arrest, can result in near-
normalisation of cardiopulmonary function and in marked
improvements in long-term survival.3 However, accurate
patient selection for this procedure is the key,4 with
inappropriate surgery leading to significant peri-operative
mortality.5 Moreover, a proportion of patients have persis-
tent disease following surgery that may become a future
target for vasoactive medical therapy.6 As such, improved
characterisation and assessment of these patients is
required, both pre- and post-operatively.
As the number of therapies available for pulmonary
hypertension expands, there is a constant search for non-
invasive tests that may serve as appropriate clinical
endpoints. Brain natriuretic peptide (BNP) is a cardiac
hormone that is released in response to high filling
pressures, limiting both systemic vasoconstriction and
sodium retention.7 In diseases of the left ventricle,
measurement of BNP is well established both as a ‘rule-
out’ test and a marker of mortality.8,9 Studies of BNP in
pulmonary hypertension, however, have been more limited,
reflecting the relative rarity of the syndrome. Nonetheless,
BNP has been shown in several forms of pulmonary
hypertension to correlate well with right ventricular
function and to be adversely associated with prognosis.10–13
BNP has also been examined in CTEPH, in a study of 34
subjects undergoing PEA.14 The results suggest that serum
BNP levels correlate with changes in haemodynamic para-
meters and may detect persistent post-operative pulmonary
hypertension, albeit with limited sensitivity and specificity.
N-terminal proBNP (NT-proBNP) is an inactive by-product
of proBNP cleavage that rises in conjunction with BNP.
Compared with BNP, NT-proBNP is stable at room tempera-
ture for prolonged periods and increases to greater levels in
pathological states.15,16 As such it offers several advantages
over BNP, making it a more practical ‘bedside’ test. Initial
evidence suggests that like BNP, NT-proBNP also correlates
well with changes in right ventricular function.17–21 How-
ever, although some subjects with CTEPH were included in
these early studies, NT-proBNP in this disease has not yet
been formally evaluated. This study therefore examines the
role of NT-proBNP in the pre- and post-operative assessment
of CTEPH patients undergoing PEA. It also compares the
relative efficacies of NT-proBNP against six minute walking
distance (6MWD), another tool that is well established in
idiopathic pulmonary arterial hypertension (IPAH) but has not
been validated in CTEPH. As the largest study to examine NT-
proBNP in subjects with pulmonary hypertension, the results
will not only provide information relevant to CTEPH, but also
to other forms of pulmonary hypertension.Study subjects
All consecutive subjects undergoing PEA surgery at Papworth
Hospital, a national PEA referral centre, between August 2004
and July 2006 were assessed for inclusion in the study. All
subjects were diagnosed with CTEPH using recognised criter-
ia.1 Subjects were considered suitable for surgery when
sufficient surgically accessible disease was demonstrated on
appropriate imaging in the presence of both significant
symptoms and deranged resting pulmonary haemodynamics.22
NT-proBNP and 6MWD are both routinely used in the
assessment of patients with pulmonary hypertension at
Papworth Hospital. As such, ethical approval was not sought,
as the study did not impose any additional burden or risk on
individual patients. However, the study was granted full
approval by the local Research & Development review board
and strict patient confidentiality was maintained through-
out.
Methods
(a) Right heart catheterisation
Right heart catheterisation was performed in accordance
with standard guidelines.23 Pre-operative results include
haemodynamic data obtained up to twelve months preced-
ing surgery. Pulmonary capillary wedge pressure (PCWP)
measurements are often unreliable in the presence of
proximal disease,4 and thus total pulmonary resistance
(TPR) was calculated for analyses involving pre-operative
data. All post-operative haemodynamic data were collected
three months following surgery. As reliable PCWP measure-
ments were obtained in all patients post-operatively,
pulmonary vascular resistance (PVR) was calculated for all
analyses that depended upon post-operative data alone.
(b) 6MWD
6MWD tests were performed as per American Thoracic
Society guidelines.24 Pre-operative results again include
data obtained within twelve months preceding surgery. Pre-
operative 6MWD data are incomplete as some subjects
underwent incremental shuttle walk testing at their
referring centre. All subjects, however, were evaluated
with 6MWD post-operatively.
(c) NT-proBNP
Blood for NT-proBNP analysis was drawn peripherally
either the day preceding surgery, for pre-operative samples,
or at the three-month assessment, for post-operative
samples. Serum NT-proBNP analysis was performed on an
Elecsys 1010 instrument (Roche Diagnostics, Basel, Switzer-
land) by sandwich immunoassay.
(d) Glomerular filtration rate (GFR)
Blood samples for serum [Creatinine] were drawn at the
same time as NT-proBNP. GFR was estimated using a
modified version of the Cockroft–Gault formula that
controlled for gender and ethnicity.25
Statistics
NT-proBNP values demonstrated a log-normal distribution and
were thus logarithmically transformed (natural logLn) prior to
ARTICLE IN PRESS
J. Suntharalingam et al.2256analysis. Means of variables were compared between groups
using paired and unpaired two sample t tests, as appropriate.
Receiver–operator curves (ROC) were drawn to identify optimal
levels of NT-proBNP and 6MWD for predicting both death and
post-operative pulmonary vascular resistance (PVR)43WU.
Associations between haemodynamic parameters, NT-proBNP
and 6MWDwere assessed using Pearson’s correlation coefficient.
The ability of NT-proBNP to predict PVR43WU was assessed by
applying a univariate logistic regression model which was then
compared to multiple models with age, sex, BMI and GFR
included as potential confounding variables. The relative
predictive strengths of NT-proBNP and 6MWD were compared
using univariate logistic regression modelling, assessing each
using the Nagelkerke R2 and the likelihood ratio test. The model
with the strongest predictor was then compared to a model
including both NT-proBNP and 6MWD, using the likelihood ratio
test to assess the relative additional contribution of the other
variable.Results
Subjects and surgical outcomes
Total 111 subjects underwent PEA during the study period.
NT-proBNP and post-operative haemodynamic data were
incomplete on 8 subjects, and thus these subjects were




Age (yr) 57.5 (14.9
Gender (%#) 55.9






Right atrial pressure (RAP) (mmHg) 9.7 (6.4)
mean Pulmonary Artery Pressure (mPAP) (mmHg) 47.6 (10.8
Cardiac output (CO) (l/min) 4.0 (1.1)
Total pulmonary resistance (TPR) (WU) 12.7 (5.2)
Pulmonary Vascular Resistance (WU)




GFR (l/min) 74.2 (30.5
Data expressed as mean (SD).
Significant pairwise comparisons are listed below.
Post-op vs pre-op in survivors (paired t-test) po0.001.
ySurvivors vs non-survivors (unpaired t-test) p ¼ 0.02.
zSurvivors vs non-survivors (unpaired t-test) p ¼ 0.04.
ySurvivors vs non-survivors (unpaired t-test) p ¼ 0.001.pulmonary sarcoma at the time of surgery, was also
excluded.
Baseline demographics and surgical outcomes at three
months are shown in Table 1. Fifteen subjects died before
completing three months. Non-survivors had significantly
worse pre-operative CO, TPR, ln[NT-proBNP] and 6MWD than
survivors. Survivors subsequently demonstrated significant
improvements in RAP, mPAP, CO, TPR, 6MWD, ln[NT-proBNP]
and GFR.
Survivors were further stratified by their three-month
post-operative PVR (Table 2) and 36/87 had normal
PVRp3WU, whilst 51/87 had persistently elevated PVR43
WU. Comparison of the pre-operative parameters of these
two groups demonstrated significant differences in mPAP,
TPR, ln[NT-proBNP], 6MWD and GFR.Pre-operative NT-proBNP
Pre-operative ln[NT-proBNP] values were significantly great-
er in non-survivors and in subjects with post-operative
PVR43WU (Tables 1 and 2). ROC analysis demonstrated an
AUC 0.79 (po0.001) for pre-operative NT-proBNP as a
predictor of death (Figure 1). A NT-proBNP levelX1200 pg/
mL achieved 93.3% sensitivity, 44.2% specificity, 97.4%
negative predictive value (NPV) and 22.6% positive pre-
dictive value (PPV) for predicting death.nths classified by survival outcome.
Post-op
s Non-survivors Survivors Survivors
(n ¼ 15) (n ¼ 87) (n ¼ 87)
) 61.2 (13.1) 56.9 (15.1)
73.3 52.9





11.8 (5.9) 9.4 (6.5) 5.9 (3.6)
) 51.7 (16.0) 46.9 (9.6) 28.6 (10.8)
3.4 (1.3)y 4.1 (1.0) 4.8 (0.8)
17.1 (9.1)z 11.9 (3.8) 6.2 (2.6)
3.9 (2.3)
.8) 182.4 (95.7)y 263.5 (150.9) 373.6 (111.3)
(n ¼ 12) (n ¼ 75)
4728 1863 624
8.1 (1.0)y 7.0 (1.3) 5.7 (1.2)
) 65.7 (30.9) 75.7 (30.4) 83.7 (33.4)
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Table 2 Baseline demographics and surgical outcomes at three months classified by post-operative PVR.
Variables Normal post-op PVR (o3) Abnormal post-op PVR (43)
(n ¼ 36) (n ¼ 51)
Pre-op Post-op Pre-op Post-op
Age (yrs) 55.2 (14.8) 58.0 (15.4)
Gender (%#) 66.7% 43.1%
BMI (kg/m2) 29.6 (5.6) 27.4 (5.1)
WHO (%)
I 0 67 0 37
II 8 28 6 41
III 67 5 65 20
IV 25 0 29 2
Right atrial pressure (RAP) (mmHg) 7.8 (7.2) 4.8 (3.1) 10.5 (5.8) 6.7 (3.7)
mean Pulmonary Artery Pressure (mPAP) (mmHg) 43.8 (9.2)y 20.3 (5.6)z 49.1 (9.3) 34.2 (10.0)
Cardiac output (CO) (l/min) 4.3 (1.1) 5.0 (0.8)y 4.0 (1.0) 4.6 (0.8)
Total pulmonary resistance (TPR) (WU) 10.6 (3.8)y 4.2 (1.3)z 12.8 (3.5) 7.6 (2.3)
Pulmonary vascular resistance (PVR) (WU) 2.0 (0.6)z 5.3 (2.0)
6MWD (m) 321 (157)y 408 (93) 223 (134) 348 (112)
NT-proBNP (pg/mL) 1493 227 2129 893
6.6 (1.4)z 5.1 (0.9)J 7.2 (1.2) 6.0 (1.2)
GFR (l/min) 84.6 (33.3) 94.0 (35.8) 69.4 (26.7) 76.4 (30)
Data expressed as mean (SD).
Significant pairwise comparisons between subjects with normal post-operative PVR vs subjects with abnormal post-operative PVR.
Post-op vs post-op p ¼ 0.01.
yPre-op vs pre-op p ¼ 0.01.
zPost-op vs post-op po0.001.
yPost-op vs post-op p ¼ 0.02.
zPre-op vs pre-op p ¼ 0.04.
JPost-op vs post-op p ¼ 0.001.
Pre-op vs pre-op p ¼ 0.02.
NT-proBNP and 6MWD in CTEPH 2257Post-operative NT-proBNP intra-individual changes
at 3 months
Ln[NT-proBNP] levels fell significantly after three months
following surgery (Table 1). The change in TPR and the
change in ln[NT-proBNP] following surgery correlated mod-
erately well (r ¼ 0.49, po0.001) (Figure 2).Figure 1 ROC curve for preoperative NT-proBNP as a predictor
of mortality.Post-operative NT-proBNP inter-individual
variations at 3 months
There were moderate correlations between post-operative
ln[NT-proBNP] and post-operative mPAP, PVR and 6MWD
(Figures 3 and 4 and Table 3).
Post-operative ln[NT-proBNP] levels differed significantly
between subjects with PVR43WU and those with PVRp3WU
(Table 2). ROC analysis demonstrated an AUC 0.71
(p ¼ 0.001) for post-operative NT-proBNP as a predictor of
PVR43WU. However, to predict PVR43WU effectively,
either a low cut-off 496 pg/mL was required to achieve
high sensitivity (90% sensitivity 25% specificity) or a high cut-
off 4531 pg/mL to achieve high specificity (91.7% specifi-
city, 43% sensitivity).
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Figure 3 Graph showing correlations between post-operative ln[NT-proBNP] and post-operative mPAP at 3 months.
Figure 2 Graph showing correlation between changes in TPR and changes in ln[NT-proBNP] following surgery.
J. Suntharalingam et al.2258NT-proBNP continued to predict PVR43WU (odds ratio
(OR) 2.26, 95% CI 1.24, 4.10) whilst controlling for BMI. Both
gender and GFR were weak confounders of NT-proBNP, and
did not alter the PVR OR by more than 10%. Greater age,
however, did adjust OR significantly and thus was a
confounding factor.Pre- and 3-month post-operative 6MWD
Analysis of 6MWD should be interpreted with caution, as
some pre-operative data were missing. ROC analysis
demonstrated an AUC 0.67 (p ¼ 0.06) for pre-operative6MWT as a predictor of death. A 6MWDp345m achieved
100% sensitivity, 36% specificity, 100% NPV and 20% PPV for
predicting death. Changes in TPR and 6MWD following
surgery correlated moderately well (r ¼ 0.46, po0.001)
(Figure 5). Correlations between post-operative 6MWD and
haemodynamic measures are shown in Table 3.
On comparing post-operative NT-proBNP and 6MWD, both
Nagelkerke’s R2 and likelihood ratio tests suggested that
NT-proBNP was the stronger predictor of PVR43WU
(NT-proBNP: r2 ¼ 0.21, po0.001 vs 6MWD: r2 ¼ 0.11,
p ¼ 0.01). Combining 6MWD with NT-proBNP did not add
further to the prediction of PVR43WU (NT-proBNP and
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Figure 4 Graph showing correlations between post-operative ln[NT-proBNP] and post-operative PVR at 3 months.
Table 3 Correlations between surgical outcomes, NT-proBNP and 6MWD.
Variables NT-proBNP 6MWD
Correlation coefficient p-value Correlation coefficient p-value
RAP (mmHg) 0.33 0.002 0.36 0.001
mPAP (mmHg) 0.65 o0.001 0.5 o0.001
CO (l/min) 0.2 0.04 0.11 ns
PVR (WU) 0.63 o0.001 0.47 o0.001
NT-proBNP (pg/mL) 0.45 o0.001
6MWD (m) 0.45 o0.001
NT-proBNP and 6MWD in CTEPH 22596MWD: r2 ¼ 0.23; NT-proBNP and 6MWD vs NT-proBNP alone
p ¼ 0.21).NT-proBNP and 6MWD intra-individual changes at 12
months
At the time of analysis, 49 subjects had completed 12
months post-surgery. NT-proBNP and 6MWD data were
available for 46 subjects. Of these, 10 had initiated
potentially disease modifying targeted therapies (8 bosen-
tan, 2 sildenafil) after their 3-month assessment, and were
thus excluded. Paired analysis of the remaining 36 subjects
showed no significant difference between 3- and 12-month
post-operative ln[NT-proBNP] values (5.2 vs 5.4, p ¼ 0.24,
95% CI 0.1, 0.5). Three- and twelve-month ln[NT-proBNP]
values correlated strongly within individuals (r ¼ 0.69,
po0.001). Conversely, three month 6MWD values were
significantly lower than twelve month values (405.2m vs
430.9m, p ¼ 0.01, 95% CI 6.7, 44.6), although the two
values continued to correlate well (r ¼ 0.84 po0.001).Discussion
This study demonstrates that pre-operative evaluation with
NT-proBNP and 6MWD helps risk-stratify patients prior to
PEA. It also shows that both tests correlate well with
haemodynamic parameters, and respond appropriately to
changes in disease burden. Of the two, NT-proBNP was the
better indicator of persistent post-operative pulmonary
hypertension, although it was confounded significantly by
age. Both investigations therefore offer valuable bedside
tools for the pre- and post-operative evaluation of CTEPH
patients undergoing PEA.
Although the pathophysiology of CTEPH differs from other
forms of pulmonary hypertension, the resulting rise in PVR
imposes a similar burden upon the right ventricle. PEA
surgery offers rapid relief from this increased afterload, and
can lead to profound improvements in right ventricular size
and function.26 However, careful patient selection is the
key.4 Not only should surgically accessible disease be
present, but patients must have minimal involvement of
their distal pulmonary vasculature. Currently, this is judged
indirectly by assessing whether the degree of segmental
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Figure 5 Graph showing correlation between changes in TPR and changes in 6MWD following surgery.
J. Suntharalingam et al.2260obstruction at angiography is proportional to the PVR at
right heart catheterisation. In support of this, several
studies have demonstrated that high pre-operative PVR is
associated with increased mortality.3,27,28 Given that this
study and others have demonstrated a correlation between
NT-proBNP and PVR,17,19,20 it is therefore not surprising that
a high pre-operative NT-proBNP also predicts poor surgical
outcome. A 6MWD is likewise correlated with PVR in this
study, and again shows a similar relationship to outcome.
Although NT-proBNPX1200 and 6MWDp345 carry low
specificity for predicting death, the high NPV of these
bedside tests suggests that they are of value in risk
stratifying patients prior to surgery.
The results include both cross-sectional and longitudinal
NT-proBNP data on a large cohort of subjects. They confirm
previous findings from PAH studies that NT-proBNP not only
correlates with right ventricular function, but is also
sensitive to changes within the underlying disease.17–20 As
such, NT-proBNP is likely to prove useful in the long-term
follow-up of patients with pulmonary hypertension. How-
ever, the ability of NT-proBNP to predict the presence of
persistent pulmonary hypertension was limited, suggesting
that it may not perform well as a screening tool. Extreme
cut-off levels were required for NT-proBNP to function
effectively as either a ‘rule-out’ or ‘rule-in’ test, implying
that solitary NT-proBNP results interpreted in isolation may
be misleading. Greater age, female gender, lower BMI and
impaired renal function are all known to increase NT-proBNP
levels in more general populations,29,30 and thus these
factors were assessed as possible confounders. In this
patient cohort, BMI was not linked with NT-proBNP, whilst
the confounding effects of gender and GFR were weak, and
unlikely to be of significance. These findings most likely
reflect the select nature of the population studied. In
particular, impaired renal function in patients with pulmon-
ary hypertension is typically due to low cardiac output
states, and is therefore unlikely to have an independenteffect on NT-proBNP levels. Age, however, did significant
confound NT-proBNP, possibly reflecting independent age-
related changes in ventricular compliance, myocardial mass
or peptide clearance.31–33 Despite this, age alone is unlikely
to explain the poor performance of NT-proBNP as a screening
tool, and it may be that genetic-dependent variations in NT-
proBNP levels are also of relevance.34
The use of 6MWD is well established in IPAH where it has
been shown to correlate with morbidity, mortality and
therapeutic responses.35,36 Although it provides less objec-
tive information than cardiopulmonary exercise testing
(CPET), it is easier to administer and less operator
dependent.37 However, the test has not been formally
validated in CTEPH, and has only been described in the
setting of PEA in one other study.38 The results from our
study, however, suggest that 6MWD does provide a reason-
able measure of disease burden in CTEPH, both in pre- and
post-operative subjects. 6MWD was able to predict surgical
outcome, reflect peri-operative changes in TPR and corre-
late post-operatively with markers of right ventricular
function. Although NT-proBNP proved a better predictor of
persistent pulmonary hypertension, presumably because it
was less patient-dependent, 6MWD nonetheless performed
well. Given its low cost and ease of use, it remains an
attractive tool for the long-term follow-up of post-surgical
patients, particularly in non-specialist settings. Further-
more, this study suggests that 6MWD may prove a useful
clinical endpoint in future trials of targeted vasoactive
therapies in inoperable CTEPH.
Although limited by numbers, the 12-month post-opera-
tive NT-proBNP and 6MWD data were also of interest. Firstly,
the strong correlation between 3- and 12-month NT-proBNP
values was reassuring, implying that the assay was repro-
ducible over time. Secondly, the static NT-proBNP
levels confirmed previous haemodynamic studies that
suggest cardiac remodelling following PEA is an early
phenomenon.39,40 Despite this plateau in haemodynamic
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to improve beyond 3 months. This uncoupling between
haemodynamic parameters and functional performance has
been described previously38 and is likely to be related to
delayed post-operative improvements in fitness and con-
ditioning.
The main limitations of this study include the lack of a
control group, and the fact that pre-operative right heart
catheterisation and 6MWD were not performed simulta-
neously with NT-proBNP analyses. In addition, despite being
the largest study to examine NT-proBNP in a cohort of
patients with pulmonary hypertension, the numbers remain
relatively small. The study does benefit, however, from the
fact that it examines a homogenous disease group and that
all subjects underwent a uniform intervention, thus redu-
cing the number of possible confounders. At the same time,
and unlike some other studies,12,20 patients were not
excluded on the basis of age or renal function, thus ensuring
the study was more applicable to the patients seen everyday
in routine clinical practice.
In conclusion, this study demonstrates that both 6MWD
and NT-proBNP are of value in CTEPH, both in risk-stratifying
patients pre-operatively and in monitoring their disease
burden post-operatively. Although confounded by age, NT-
proBNP was not affected significantly by gender, BMI or renal
function. These results suggest that both NT-proBNP and
6MWD offer potentially valuable ‘bedside’ endpoints for the
long-term follow-up of patients with CTEPH. In addition, as
the largest study to examine NT-proBNP in pulmonary
hypertension, the study provides useful data that may be
extrapolated for use in other forms of the disease.
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